NCAM1 and neoplasm: Relapse or death was observed in 12 patients of the vitamin D group (11.1%), which was significantly lower than in the placebo group (19 patients, 24.4%) in the subgroup with the higher half of CD56+ cells infiltrating in tumor stroma (HR, 0.42; 95%CI, 0.20–0.87) (Figure 5A), but equivalent (vitamin D vs. placebo = 32 patients (28.8%) vs. 21 (28.0%)) in the subgroup with the lower half (1.13; 95%CI, 0.65–1.97) (Figure 5B).